STOCKS TELEGRAPH

Author: ST Staff

  • Arvinas, Inc. (ARVN) Stock on the Rise Following Global Partnership with Pfizer

    Arvinas, Inc. (ARVN) stock prices were up by 8.68% some time after market trading commenced on July 22nd, 2021, bringing the price per share up to USD$84.28 early on in the trading day.

    Partnership with Pfizer

    July 22nd, 2021 saw the company announce its global collaboration with Pfizer in order to develop and commercialize ARV-471, an investigational oral PROTAC, estrogen receptor protein degrader. The estrogen receptor has been shown to drive diseases in most cases and forms of breast cancer. The treatment is currently in Phase 2 dose expansion clinical trial, designed to treat patients with estrogen receptor (ER) positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-).

    Details of the Agreement

    As per the agreement, the partnering company will make an upfront payment of USD$650 million to ARVN, as well as a USD$350 million equity investment in the company. Global development costs, commercialization expenses, and profits will be split equally between the partnering companies. The combination of the company’s leadership in targeted protein degradation with Pfizer’s global capabilities and extensive expertise in breast cancer is expected to prove transformational.

    Scope of ARV-471

    This, in turn, will substantially enhance and accelerate the development and eventual commercialization of ARV-471 while concurrently advancing the company’s strategy of building a global and integrated biopharmaceutical company. Despite the advancement of the oncology space over recent years, there is still a sizeable unmet need that persists in the treatment of HR+ breast cancer. The partnership with Pfizer will see the deployment of PROTAC technology in a bid to help mitigate the devastation caused by the disease.

    ARV-471’s Potential

    December 2020 saw the company present interim data for its Phase 1 dose-escalation clinical trial of ARV-471 in patients with locally advanced or metastatic ER+/HER2- breast cancer. The treatment is indicated for its potential as a novel oral ER targeted therapy. Patients enrolled in the study were heavily pretreated, having been administered with cyclin-dependent kinase (CDK) 4/6 inhibitors. Despite the extensive pretreatment and the advanced stage of disease, the interim results demonstrated the treatment’s ability to promote substantial ER degradation and exhibits an encouraging clinical efficacy and tolerability profile.

    Future Outlook for ARVN Stock

    Armed with a massively expansive collaboration with Pfizer, the company is keen to make the most of the opportunities afforded to it as it expands and consolidates its market footprint. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to usher in organic growth over the long term.

  • Cuentas, Inc. (CUEN) Stock Soars Following Definite Agreement Between Cuentas and WaveMax

    Cuentas, Inc. (CUEN) stock prices were up 18.82% as of the market opening on July 22nd, 2021, bringing the price per share up to USD$4.23 early on in the trading day.

    Agreement with Wavemax

    July 22nd, 2021 saw the company announce having signed an exclusive, definitive JV agreement to rollout WaveMax’s SharedWiFi6 patented technology in 1000 locations. The rollout will commence from the New York City Metropolitan Area, with 500 locations in NYC, 330 in New Jersey, and 170 in Connecticut, with additional rollouts planned throughout the rest of the United States. The collaborative partners will execute a 50/50 joint venture to install advanced WiFi6 Access Points and Small Cells across the 1000 Bodega Stores.

    Implementing WaveMax Tech

    The stores will become CUEN’s premium locations that will be situated near public train stations and mass transit hubs, with the company’s products and services being offered on secure networks. The WiFi6 service is designed to enhance customer experiences with the Bodega stores with the automatic connecting of users with SharedWiFi high-speed internet, extending the reach of special in-store offers. Consumers at CUEN Points of Sale locations will also have access to promotions for the Cuentas GPR card and discounted products offered for sale through the company’s mobile app.

    CUEN’s Foray into Advertising

    The unique agreement will facilitate CUEN’s entry into the advertising ecosystem with its use of major brands to advertise the company’s offerings through mobile handsets. Furthermore, the company’s products and services will be available at a 50% discount for most favored nation pricing on their digital advertising platform.

    Advertising Ecosystem

    The company’s proprietary WaveMax’s SharedFi patented technology ensures the provision of a shared network of WiFi access points and small cells. Users will have access to the shared network and will have the option of being targeted by location-based advertising. The ads are configured by advertisers making use of WaveMax’s dashboards, which can manually or automatically target suitable demographics in an efficient manner.

    Future Outlook for CUEN

    Armed with the proliferation of its WaveMax technology and its rollout agreement, CUEN is poised to massively expand the scope of its market footprint. Keen to increase accessibility and market penetration, CUEN is confident in its ability to continue its trajectory of success. Investors are hopeful that management will persist in the effective management of company resources to usher in organic growth over the long term.

  • India Globalization Capital Inc. (IGC) stock surged in the current trading session; Here’s why this is happening

    In the current trading session, India Globalization Capital Inc. (IGC) stock is racking up the prices of its shares by up to 141.89% to trade at the price of $3.58 at the last check. IGC stock previously closed the session at $1.48. The IGC stock volume traded 138.38 million shares today. In the past year up to datemIGC shares have surged by 154.60% and in the past week moved up by 3.50%. India Globalization Capital Inc. is currently valued in the market at $61.09 million and has 45.11 million outstanding shares.

    An overview of India Globalization Capital Inc.

    India Globalization Capital Inc. can be labeled as a conglomerate that focuses mainly on the purchasing and reselling of physical infrastructure commodities. There are two operational segments of the IGC stock’s business model. These segments include Infrastructure Business and Life Sciences. The company is involved in the trading of infrastructure commodities; buying and selling which includes wooden doors, tiles, steel, and marbles, etc. The infrastructure business segment also includes acquiring and renting heavy construction equipment and undertaking highway construction contracts.

    The Life Sciences segment of the company is currently seeing a trend in cannabinoid-based products and has thus started developing cannabinoid-based items and treatments, like Hyalolex for the treatment of patients from uneasiness, disturbance, dementia, melancholy, and rest issue illnesses. India Globalization Capital also focuses on hemp-based CBD imbued items under the Holief brand name; premium hemp-based CBD mixed natural skin and spa line of items under the Herbo brand name, and premium hemp-based CBD implanted seltzer under the Sunday Seltzer brand. Furthermore, it offers offer exchanging, refining, ringing, and white marking administrations under the Holi Hemp brand; and hemp rough concentrates, hemp detaches, and hemp distillates

    The conglomerate has expanded its operations in United States, India, Colombia, and Hong Kong. IGC stock was originated in 2005 and the company is based in Potomac, Maryland.

    Development of IGC’s THC based Alzheimer treatment and its patency

    The IGC stock is keeping up with the trends and growth in the marijuana and cannabis market as more and more states and countries ease down the criminalization law of cannabis. Furthermore, the company has also tapped into the medicinal marijuana and cannabis market which is fairly more legalized than recreational marijuana usage. IGC stock announced on 20th July 2021, that USPTO which stands for United States Patent and Trademark Office has issued a patent for the company’s proprietary development of Alzheimer’s treatment. This treatment is based on the THC dosage which acts as a potential therapeutic and prophylactic agent for the treatment of Alzheimer’s disease.

    The Company as of late reported the fulfillment of Cohort 3 in its fake treatment controlled Multiple Ascending Dose (MAD) stage 1 preliminary for setting up safety and potency of IGC-AD1 that utilizes THC on patients experiencing Alzheimer’s sickness.

    The unique patent application was started by the University of South Florida (“USF”) and documented on August 1, 2016. On May 25, 2017, IGC went into a selective permit concurrence (ELA) with USF concerning the patent application and the related examination led on Alzheimer’s infection.

  • Summit Wireless Technologies, Inc. (WISA) stock is Popping High today: Why is it so?

    Summit Wireless Technologies, Inc. (WISA) stock announced the launch of its custom Amazon storefront after which the stock price saw a push of  40.79% to reach $5.73 a share as of this writing. The momentum was already created in the previous trading session as WISA stock went high by 16.95% at closing. Let’s deep dive to explore more of it.

    What’s Happening?

    Summit Wireless Technologies, Inc. is engaged in the developing, manufacturing, and selling of integrated circuits for home entertainment as well as the audio market in the United States and many other countries across the globe. The stock announced the launching of its Amazon Storefront through which it would sell its all-certified products. The customer experience would be strengthened as the WISA products would be purchased easily from one page.

    WiSA’s Amazon storefront will play a major role in the continued growth of the global wireless WiSA Certification category that includes wireless transmitters, TVs and WiSA surround sound configurations in which Dolby Atmos is also included.

    WiSA Wave Marketing Program:

    WISA stock is expecting 2 million visitors to its website due to the success of its efficient WiSA Wave  Marketing Program. The team is working closely with consumer electronic members in order to create a successful dedicated online store. The wave marketing campaign is focused on educating the benefits of WiSA to its target audience. The wave initiatives also emphasizing the benefits of home cinema experiences that member brands are delivering to their consumers.

    WiSA SoundSend Certified Program:

    Yesterday on July 21, 2021, WISA stock did announce that it has launched its WiSA SoundSend Certified Program. The purpose of this initiative by the WISA stock is to work with TV manufacturers in order to make a simple and flawless connection and interoperability with the WiSA SoundSend wireless audio transmitter along with Toshiba TV “REGZA”.This will be the first TV brand that will deliver solutions with the new certifications.

    After passing the successful test to work perfectly with SoundSend, Smart TVs will then get the WiSA SoundSend certified status. The test will include all the audio connections as well as control requirements between Smart TV and SoundSend.

    Conclusion:

    Things are going well for WISA stock as far as market sentiment is concerned. The Amazon StoreFront and WiSA SoundSend Certified program would significantly help in the growth of the stock.

  • Seres Therapeutics Inc. (MCRB) stock plunged in the premarket trading session; here’s why

    It was observed in the last check, that Seres Therapeutics Inc. (MCRB stock) shares had plunged in the premarket trading session. The double-digit plunge had shed-58.09% off of the share price bringing it at $8.73 in pre-market. MCRB stock had closed the previous session on Thursday with a gain of 0.48% at $20.83. The MCRB stock volume traded 0.87 million shares, while in the past 50 days the average trade volume per day was around 0.87 million shares. In the past year up to date, MCRB shares have jumped by 338.53% and in the past week, the MCRB stock moved up by 1.61%. In the past three and six months, the stock has gained 1.66% and shed -17.99% respectively. Furthermore, the company is currently valued at $1.86 billion and has 91.53 million outstanding shares.

    About Seres Therapeutics Inc.

    Seres Therapeutics Inc. is a biotechnology company that specifically focuses on the development, discovery, and licensing of disease-treating therapeutics. The therapeutics is based on a microbiome platform that creates bacterial consortia. The bacterial consortia’s primary function is to interact with the host cells and tissues in a therapeutic way to treat the disease.

    The organization’s lead item up-and-comer is the SER-109, an oral microbiome helpful competitor that has finished Phase III clinical preliminary for the treatment of clostridium difficile disease (CDI). It is likewise creating SER-287 that is in Phase IIb clinical preliminary to treat ulcerative colitis; SER-401, which is in Phase Ib clinical preliminary for use with designated spot inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical preliminary for the treatment of incendiary entrail sickness. What’s more, the organization participates in the improvement of SER-262 to treat an underlying repeat of CDI; and SER-155, a developed microorganisms microbiome drug intended to forestall mortality because of gastrointestinal contaminations, bacteremia, and join versus have illnesses in immunocompromised patients getting allogeneic hematopoietic undifferentiated cell transplantation and organ transfers.

    The company’s platform and progress allows it to have licensing partnerships with other medical institutions and firms across the industry. It has made these sort of partnerships with Memorial Sloan Kettering Cancer Center and NestecLTd. The company was originally formed in 2010 by the name of Seres Health Inc. which was changed in May 2015. Furthermore, the headquarter of the company lies in Cambridge, Massachusetts.

    MCRB stock is holding a meeting regarding the topline results of the phase 2b trial of ECO-RESET study

    By Easter Time 8:30 am today, the MCRB stock had been hosting a conference call and live audio webcast. This conference was specifically hosted by the management team at Seres Therapeutics Inc. The main reason for hosting this live call and conference is to address the results from the phase 2b ECO-RESET study which had evaluated SER-287 in patients with mild-to-moderate ulcerative colitis (UC). The company provided topline results for this phase 2b study which listed that the Essential endpoint of clinical abatement contrasted with fake treatment was not accomplished; both dosing regimens of SER-287 were for the most part very much endured; open name and support parts of the SER-287 examination will be shut and Microbiome endpoints and examinations expected in the second 50% of 2021.

  • Here’s Why Clover Health Investments Corp.’s (CLOV) stock rose in premarket trading session

    Shares of Clover Health Investments Corp. (CLOV stock) started to rise by 6.08% and in pre-market traded at $9.42. There was a gain in CLOV stock of 6.35% and closed at $8.88 on Thursday’s session. CLOV’s stock volume stayed the same at 30.19 million shares, however, this was lower than the average volume of the past 50 days which was 63.42 million shares. Over the last 1 year, there has been a decline in shares of CLOV stock by -20.22%, and the last week they have risen up 2.3%. CLOV stock has declined by -1.88% over the last three months and in the last six months, the CLOV stock value has decreased by -35.32%. The outstanding shares of Clover Health stand at 376.17 million and the current market value is $3.65 billion.

    Overview of Clover Health Investments Corp.

    Clover Health Investments Corp., founded in 2014, is an American-based Medicare advantage insurer company, whose mission is to improve all life. It is a risk-taking organization that, through its software platform, aims to provide health equity to Americans and provides health plans for eligible customers. Clover Health Investments Corp. focuses primarily towards senior citizens who previously did not have access to high-quality, affordable healthcare. Clover health adds value to its customers by providing them plans that are budget-friendly. They also help the customers in applying for programs that can help them in paying for the prescriptions, premiums as well as utility bills. It is currently headquartered in Franklin, Tennessee.

    Announcement regarding second-quarter financial results of 2021

    In a recent announcement, Clover Health said that they will report their second-quarter financial results of 2021 0n 11th August 2021 after the market close. The management of clover health will host a webcast and a conference call at 5 p.m. ET to disclose the financial results as well as the business results.
    Some of the details of the conference call and webcast for the second quarter include a live-streamed webcast of the call that can be accessed from their investors’ page on the website and it will be archived so it can be accessed for about twelve months.

    Breach of fiduciary duties investigations

    In another recent event, it has been found out that Kehoe Law Firm, P.C. is investigating that weather certain board of directors have failed to fulfill their duties and have been unable to manage CLOV in an acceptable way and whether as a result of this negligence, the shareholders have suffered damage or not. On the 5th of October, 2020, there was a merger agreement of Social Capital Hedosophia III with a predecessor to Clover Health and had a record date for shareholder vote as 17th November, 2020. The merger transaction was closed by Social Capital Hedosophia III on 7th January 2021, making Clover Health the successor entity. Later on, there was a report issued by Hindenburg Research in February that claimed that Clover Health had been hiding governmental investigations from the public.

  • Lexaria Bioscience Corp. (LEXX) Stock Showing Increased Volatility Ahead of Success of Antiviral Drug Studies

    Lexaria Bioscience Corp. (LEXX) stock prices soared by 28.07% at the end of the trading day on July 21st, 2021, bringing the price per share up to USD$8.44 at the end of the trading day. Subsequent premarket fluctuations have seen the stock fall by 11.14%, bringing it down to USD$7.50.

    DehydraTECH Evaluation

    The company reported having successfully met its objectives for its 2021 antiviral drug examination program designed to evaluate DehydraTECH. The technology exhibited evidence of superior oral absorption of its processed compounds of leading classes of antiviral drugs for Covid-19, HIV/AIDS, and other infection diseases. DehydraTECH was also evaluated in regard to its processing of those compounds managing to preserve expected viral inhibitory performance, guided by efficacy testing in infected mammalian cells. The treatment was also proven to not adversely affect the drug molecules chemically, thereby creating new molecular entities that would prove to be difficult in guiding through the regulatory approval process.

    Continued Development

    To this end, LEXX is allocating resources towards a comprehensive multi-pronged program. It is designed to demonstrate essential proof-of-concept safety, efficacy, and formulation/scalability feasibility data to potential pharmaceutical industry partners. This is in line with the company’s strategy to create additional value-adding opportunities for further collaborative product development.

    Expanding Market Footprint

    The company is keen to leverage its DehydraTECH technology to pursue strategic collaboration opportunities with established industry partners who may be incorporating the technology with antiviral drugs. The company is striving to prove DehydraTECHworks to enhance oral delivery characteristics of relevant drugs, with its scope extending to other related treatments as well. Cumulatively, the company hopes to help develop treatments to fight a myriad of virus triggered diseases, including, but not limited to, shingles, influenza, viral forms of gastroenteritis, hepatitis, meningitis, and pneumonia.

    Scope of DehydraTECH

    Despite the efficacy and accessibility of vaccines to prevent many viral infections, thousands of people die annually from viral infections while being unvaccinated. Current estimations peg more than 99% of the 200,000 US death since January 1st, 2021 as a result of the Covid-19 pandemic being in people who were unvaccinated. This demonstrates the vital and expansive existing need for successful treatment options for those who are unvaccinated.

    Future Outlook for LEXX

    Armed with the continued proliferation of its flagship DehydraTECH technology, LEXX is poised to capitalize on the opportunities arising from its expanding network of strategic partners. Current and potential investors are hopeful that management will continue to leverage the resources at its disposal to facilitate significant and sustained increases in shareholder value.

  • NETGEAR, Inc. (NTGR) stock is Going down today: Why is it so?

    NETGEAR, Inc. (NTGR) stock announced second-quarter 2021 ended June 27, 2021, financial results after which the NTGR stock price saw a decline of 15.00% to drop at $31.50 a share at the time of this writing. The stock was previously gaining in the trading session and closed with a 0.62% rise. Let’s discuss the recent events of the NTGR stock in detail.

    Financial Results:

    • The net revenue in the second quarter of 2021 for the NTGR stock increased by 10.3% to reach $308.8 million as compared to the prior-year quarter.
    • NTGR stock reported $21.5 million GAAP operating income in the reported quarter as compared to $8.9 million in the comparable quarter of the previous year.
    • Non-GAAP operating income for the reported quarter was $26.5 million as compared to $21 million in the same quarter of the previous year.
    • GAAP net income was reported at $0.57 per diluted share in the second quarter of 2021 as compared to $0.20 in the same prioryear quarter.
    • The non-GAAP net income of the NTGR stock was $0.66 per diluted share as compared to $0.54 in the comparable quarter of the previous year.
    • Net income for the NETGEAR stock was 17.8 million, or 57 cents a share lesser than the net income of $22.96 million, or 72 cents a share in the same tenure of the previous year.

    Third Quarter Outlook:

    • The third-quarter revenue for the NTGR stock is expected to be between $285 million to $300 million.
    • GAAP operating margin is expected to be in the range of 2.1% to 3.1% while non-GAAP operating margin is estimated between 5.0% to 6.0%.
    • The stock expects its GAAP and non-GAAP tax rate to be approximately 27.5% and 24.5% respectively.

    New Appointments:

    NETGEAR stock on July 21, 2021, announced the appointment of  David J. Henry to the company’s board of directors. Furthermore, the NTGR stock reported his promotion to President & GM of Connected Home Products and Services. In 2004, David became part of NETGEAR and took the responsibility of product line manager for Wifi routers. On the other hand, Gregory J. Rossmann will step down from the board and will transition to his next professional role. Gregory served NETGEAR for almost two decades.

    Conclusion:

    Though financial results represent 10.3% topline growth over the year, still it missed the net income estimates that made the stock gloomy today. The factory closure due to Covid-19 has done the damage as the stock falls short of its operating margin goals.

  • Texas Instruments Inc. (TXN) Stock Exhibits Minor Volatility Ahead of Lukewarm Profit Forecast

    Texas Instruments Inc. (TXN) stock prices were up 3.45% as of the market close on July 22nd, 2021, bringing the price per share up to USD$194.24 at the end of the trading day. Subsequent premarket fluctuations saw the stock fall by 4.86%, bringing it down to USD$184.80.

    Soft Financial Expectations

    Despite the company’s revenue forecast for the current fiscal period disappointing some investors, the company is confident regarding its trajectory of success. Investors are concerned that the recent momentum seen in chip demand growth caused by the onset of the global coronavirus pandemic will be short-lived. TXN reported expecting sales ranging from USD$4.4 billion to USD$4.76 billion for the fiscal quarter ending in September of 2021, representing a profit per share ranging from USD$1.87 to USD$2.13 a share.

    Changing Marketspace

    In line with the success seen by the chipmaking sector, TXN has reported several consecutive quarters of double-digit percentage revenue growth, largely driven by increases in demand for a range of devices that use the company’s tiny electronic components. The extent of the growth seen by the sector has raised concerns that at least some of the movement is a result of panic buying from customers concerned about future shortages, that may not actually occur. Such stockpiling behavior has historically been associated with crashes.

    Lower Inventory Levels

    The company’s management reported in-house inventory having fallen to 111 days for the quarter, down from the average of 130 to 190 days it has typically maintained. The length of time between the placement of an order and the delivery to customers referred to as the lead time, has been increasing for an increasing range of TXN’s offerings.

    About TXN

    TXN, which is based out of Dallas, has an extensive catalogue of products in the tens of thousands and a massive customer base of more than 100,000. The company manufactures an array of products ranging from phones to military hardware and addresses a substantial chunk of the electronics market, facilitated by its extensive reach as the largest manufacturer of analog and embedded processing chips. The industrial machinery sector is particularly significant supplied by the company’s offerings.

    Future Outlook for TXN

    Despite the company not being able to maintain its recent trajectory of success, TXN is poised to capitalize on strategic opportunities to ensure an organic acceleration of its growth. The company is keen to adapt to the evolving chip market, with its decisions being founded in evidence-based foresight. Investors are hopeful that the company will be able to usher in significant and sustained increases in shareholders.

  • Second Sight Medical Products Inc. (EYES) stock surged in the premarket trading session; here’s why

    In the premarket trading session, we observe that Second Sight Medical Products Inc. (EYES stock) shares had surged by 17.59% to trade at the price of $5.08 last check. EYES stock had previously closed the session on Thursday whilst gaining 12.21% at a share price of $4.32. The EYES stock volume traded 12.36 million shares, while for the past 50 days the average daily volume trade was 6.46 million shares. In the past year up-to-date EYES shares have jumped up by 348.78% and in the past week, the shares climbed 12.21%. In the past three and six months, the EYES stock had shed -40.98% and added 117.09% respectively. Furthermore, the EYES stock is currently valued in the market at $164.68 million and has 23.54 million outstanding shares.

    All you need to know about Second Sight Medical Products’ as a company

    Second Sight Medical Products is as the company name suggests a medical devices company. EYES stock focuses on the development and marketing of visual prosthetics that are implantable. These product offerings of Second Sight Medical Products are aimed to provide artificial vision to blind individuals. This means that the company targets the market of blind individuals in an effort to bridge the gap of visual impairment. The platform of operations it has created for this market provides technologically innovated products for sight-impairment. The company’s product offering includes Orion Visual Cortical Prosthesis System, an embedded cortical incitement gadget, which is proposed to give valuable fake vision to people who are visually impaired because of different causes, including glaucoma, diabetic retinopathy, optic nerve injury or sickness, and eye injury. The organization was established in 1998 and is settled in Sylmar, California.

    Closing of underwriting for the 10 million shares of EYES stock announced by the company

    On 23rd June 2021, Second Sight Medical Products, Inc. announced that it made a public offering price for its underwritten offer of 10 million shares of common EYES stock. The pricing was set at $5.00 per share which totaled the whole public offering to a value of $50 million. This, of course, is separate from the underwriting discounts and commissions along with other expenses that will take place from this gross proceeds.

    The company is creating and developing its Orion Visual Cortical Prosthesis System and has stated capital funding for this to be the primary reason for expanding the gross proceeds from the public underwritten offering.

    The underwriting also includes the granting of a 45-day option for the purchase of an additional 1.5 million share of common EYES stock. This is done with the intention to cover over-allotments. It is clear by the indication of the company’s intent for the gross proceeds that this offering was made solely by the company.

    The closing of this underwriting took place on 25th June 2021, along with satisfactory compliance of customary closing conditions. The company had appointed ThinkEquity as the sole book-running manager for the offering. ThinkEquity is a division of Fordham Financial Management Inc.